Voluntary announcement - ascletis' oral small molecule glp-1, ASC30, demonstrated placebo-adjusted HBA1C reduction of 1.7% at 12 weeks from its U.S. phase ii study in participants with diabetes
Filed with HKEX · Stock code 1672 ·
6ix is reading this filing.
View original source (HKEXnews)Ascletis Pharma, Inc. on 6ix
Earlier from Ascletis Pharma
- Next Day Disclosure Return
- Voluntary announcement - ascletis announces FDA ind submission of ASC39, an oral small molecule selective amylin receptor agonist for the treatment of obesity
- Voluntary announcement - ascletis' strategic partner sagimet announces first patient dosed in phase iii U.S. clinical trial of denifanstat (ASC40) for moderate to severe acne
- Voluntary announcement - ascletis announces positive preclinical data for the most comprehensive once-weekly oral peptide pipeline for the treatment of obesity
Follow Ascletis Pharma into a list and get an email when it puts out news.
Follow Ascletis Pharma